VERRICA PHARMACEUTICALS INC (VRCA) Fundamental Analysis & Valuation

NASDAQ:VRCA • US92511W2070

6.26 USD
+0.28 (+4.68%)
At close: Mar 11, 2026
6.38 USD
+0.12 (+1.92%)
After Hours: 3/11/2026, 6:33:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This VRCA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to VRCA. VRCA was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of VRCA have multiple concerns. While showing a medium growth rate, VRCA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. VRCA Profitability Analysis

1.1 Basic Checks

  • In the past year VRCA has reported negative net income.
  • In the past year VRCA has reported a negative cash flow from operations.
  • In the past 5 years VRCA always reported negative net income.
  • VRCA had a negative operating cash flow in each of the past 5 years.
VRCA Yearly Net Income VS EBIT VS OCF VS FCFVRCA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • VRCA has a worse Return On Assets (-63.61%) than 67.88% of its industry peers.
Industry RankSector Rank
ROA -63.61%
ROE N/A
ROIC N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VRCA Yearly ROA, ROE, ROICVRCA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 91.36%, VRCA belongs to the top of the industry, outperforming 92.75% of the companies in the same industry.
  • VRCA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VRCA Yearly Profit, Operating, Gross MarginsVRCA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. VRCA Health Analysis

2.1 Basic Checks

  • VRCA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for VRCA has been increased compared to 1 year ago.
  • VRCA has more shares outstanding than it did 5 years ago.
  • VRCA has a worse debt/assets ratio than last year.
VRCA Yearly Shares OutstandingVRCA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
VRCA Yearly Total Debt VS Total AssetsVRCA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -10.20, we must say that VRCA is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of VRCA (-10.20) is worse than 69.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.2
ROIC/WACCN/A
WACC11.7%
VRCA Yearly LT Debt VS Equity VS FCFVRCA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

  • A Current Ratio of 1.25 indicates that VRCA should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.25, VRCA is doing worse than 76.17% of the companies in the same industry.
  • VRCA has a Quick Ratio of 1.18. This is a normal value and indicates that VRCA is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.18, VRCA is doing worse than 72.54% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.18
VRCA Yearly Current Assets VS Current LiabilitesVRCA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. VRCA Growth Analysis

3.1 Past

  • VRCA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 81.37%, which is quite impressive.
  • VRCA shows a strong growth in Revenue. In the last year, the Revenue has grown by 234.73%.
  • VRCA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -14.25% yearly.
EPS 1Y (TTM)81.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.39%
Revenue 1Y (TTM)234.73%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%905.39%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.35% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 83.00% on average over the next years. This is a very strong growth
EPS Next Y89.89%
EPS Next 2Y38.63%
EPS Next 3Y25.73%
EPS Next 5Y17.35%
Revenue Next Year324.96%
Revenue Next 2Y84.56%
Revenue Next 3Y90.54%
Revenue Next 5Y83%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VRCA Yearly Revenue VS EstimatesVRCA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
VRCA Yearly EPS VS EstimatesVRCA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10 -15

More info and screens

Find the best growth stocksShow best growing peers

1

4. VRCA Valuation Analysis

4.1 Price/Earnings Ratio

  • VRCA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VRCA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VRCA Price Earnings VS Forward Price EarningsVRCA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VRCA Per share dataVRCA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • VRCA's earnings are expected to grow with 25.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.63%
EPS Next 3Y25.73%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VRCA Dividend Analysis

5.1 Amount

  • No dividends for VRCA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VRCA Fundamentals: All Metrics, Ratios and Statistics

VERRICA PHARMACEUTICALS INC

NASDAQ:VRCA (3/11/2026, 6:33:01 PM)

After market: 6.38 +0.12 (+1.92%)

6.26

+0.28 (+4.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-11
Earnings (Next)N/A
Inst Owners32.57%
Inst Owner Change106.8%
Ins Owners30.12%
Ins Owner Change11.79%
Market Cap100.10M
Revenue(TTM)30.83M
Net Income(TTM)-26.01M
Analysts81.82
Price Target16.83 (168.85%)
Short Float %5.07%
Short Ratio2.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)99.21%
Min EPS beat(2)95.64%
Max EPS beat(2)102.78%
EPS beat(4)3
Avg EPS beat(4)52.06%
Min EPS beat(4)-0.55%
Max EPS beat(4)102.78%
EPS beat(8)5
Avg EPS beat(8)23.1%
EPS beat(12)7
Avg EPS beat(12)14.8%
EPS beat(16)10
Avg EPS beat(16)22.31%
Revenue beat(2)2
Avg Revenue beat(2)166.29%
Min Revenue beat(2)140.71%
Max Revenue beat(2)191.87%
Revenue beat(4)3
Avg Revenue beat(4)74.63%
Min Revenue beat(4)-67.61%
Max Revenue beat(4)191.87%
Revenue beat(8)6
Avg Revenue beat(8)40.7%
Revenue beat(12)8
Avg Revenue beat(12)63.65%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.72%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.25
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.41
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.81
FCFYN/A
OCF(TTM)-1.81
OCFYN/A
SpS1.93
BVpS-1.07
TBVpS-1.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.61%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.36%
FCFM N/A
ROA(3y)-92.78%
ROA(5y)-75.94%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.53%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.18
Altman-Z -10.2
F-Score4
WACC11.7%
ROIC/WACCN/A
Cap/Depr(3y)45.1%
Cap/Depr(5y)835.39%
Cap/Sales(3y)3.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)81.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%99.39%
EPS Next Y89.89%
EPS Next 2Y38.63%
EPS Next 3Y25.73%
EPS Next 5Y17.35%
Revenue 1Y (TTM)234.73%
Revenue growth 3Y-14.25%
Revenue growth 5YN/A
Sales Q2Q%905.39%
Revenue Next Year324.96%
Revenue Next 2Y84.56%
Revenue Next 3Y90.54%
Revenue Next 5Y83%
EBIT growth 1Y78.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.93%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.2%
OCF growth 3YN/A
OCF growth 5YN/A

VERRICA PHARMACEUTICALS INC / VRCA FAQ

What is the ChartMill fundamental rating of VERRICA PHARMACEUTICALS INC (VRCA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to VRCA.


Can you provide the valuation status for VERRICA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to VERRICA PHARMACEUTICALS INC (VRCA). This can be considered as Overvalued.


Can you provide the profitability details for VERRICA PHARMACEUTICALS INC?

VERRICA PHARMACEUTICALS INC (VRCA) has a profitability rating of 1 / 10.


How financially healthy is VERRICA PHARMACEUTICALS INC?

The financial health rating of VERRICA PHARMACEUTICALS INC (VRCA) is 1 / 10.